Corrigendum to “A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation–positive NSCLC in Whom Systemic Disease (T790m-Negative) Progressed after Treatment with First- or Second-Generation EGFR TKI and Platinum-Based Chemotherapy” [lung Cancer 177 (2023) 44–50]